Skip links

Amondys 45™ (casimersen)

Full Name Amondys 45™ (casimersen)
Drug Amondys 45
Manufacturer Sarepta Therapeutics, Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping
Disease Duchenne Muscular Dystrophy (DMD)
Therapeutic Area Neurology
Enrollment Form Link Enrollment Form
Orsini Home Infusion Form
Phone Number 800-356-5034
Fax Number 877-339-4602
Product Website amondys45.com
Patient Resources Alex Rezcalla Foundation, Jett Foundation, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy